Research programme: protein kinase inhibitors - PIQUR Therapeutics

Drug Profile

Research programme: protein kinase inhibitors - PIQUR Therapeutics

Alternative Names: PQR-311; PQR-316; PQR-3xx; PQR-401; PQR-5xx; PQR-620

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator PIQUR Therapeutics
  • Class Antineoplastics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Janus kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain disorders; Cancer; Eye disorders; Skin disorders

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 28th Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 21 Apr 2016 Preclinical in Cancer, Skin disorders, Eye disorders and Brain disorders in Switzerland (unspecified route)
  • 21 Apr 2016 Results from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top